These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18097108)

  • 1. A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology.
    Odabaşi AR; Yüksel H; Demircan SS; Kaçar DF; Culhaci N; Ozkara EE
    J Postgrad Med; 2007; 53(4):221-7. PubMed ID: 18097108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine effects of different estradiol-progestin regimens in postmenopausal women.
    Stomati M; Bersi C; Rubino S; Palumbo M; Comitini G; Genazzani AD; Santuz M; Petraglia F; Genazzani AR
    Maturitas; 1997 Dec; 28(2):127-35. PubMed ID: 9522320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial.
    Casanova G; Spritzer PM
    Lipids Health Dis; 2012 Oct; 11():133. PubMed ID: 23046709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
    Baksu B; Baksu A; Göker N; Citak S
    Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns.
    Di Carlo C; Tommaselli GA; Gargano V; Savoia F; Bifulco G; Nappi C
    Climacteric; 2010 Oct; 13(5):442-6. PubMed ID: 20575654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women.
    Noé G; Sitruk-Ware R; Zegers-Hochschild F; Variano B; Montero JC; Arriagada P; Li A; Stanczyk FZ; Felix JC; Mishell DR; Croxatto HB
    Climacteric; 2010 Oct; 13(5):433-41. PubMed ID: 20642326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
    Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
    Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
    Archer DF; Pickar JH; MacAllister DC; Warren MP
    Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
    Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
    Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
    Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of intranasal and transdermal estradiol.
    Lopes P; Merkus HM; Nauman J; Bruschi F; Foidart JM; Calaf J
    Obstet Gynecol; 2000 Dec; 96(6):906-12. PubMed ID: 11084176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
    Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
    Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.